

SUN PHARMA GLOBAL INC  
 Form 4  
 February 02, 2006

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 SUN PHARMACEUTICAL  
 INDUSTRIES LTD

2. Issuer Name and Ticker or Trading Symbol  
 CARACO PHARMACEUTICAL  
 LABORATORIES LTD [CPD]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 SPARC, TANDALJA  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 11/24/2004

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 \_\_\_X\_\_\_ 10% Owner  
 \_\_\_\_ Other (specify below)

VADODARA, GUJARAT, K7 309  
 020  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_\_\_ Form filed by One Reporting Person  
 \_\_\_X\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock				(A) or (D)	8,382,666 <sup>(1)</sup>	D <sup>(2)</sup>	
Common Stock				(A) or (D)	8,486,014 <sup>(1)</sup>	I	See Footnote <sup>(3)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

Edgar Filing: SUN PHARMA GLOBAL INC - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	11/24/2004		J <sup>(5)</sup>		544,000		11/24/2007 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	12/06/2004		J <sup>(5)</sup>		544,000		12/06/2007 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	01/25/2005		J <sup>(5)</sup>		544,000		01/25/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	03/05/2005		J <sup>(5)</sup>		544,000		03/05/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	03/22/2005		J <sup>(5)</sup>		544,000		03/22/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	05/02/2005		J <sup>(5)</sup>		544,000		05/02/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	07/11/2005		J <sup>(5)</sup>		544,000		07/11/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	07/14/2005		J <sup>(5)</sup>		544,000		07/14/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	08/25/2005		J <sup>(5)</sup>		544,000		08/25/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	10/27/2005		J <sup>(5)</sup>		544,000		10/27/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	12/31/2005		J <sup>(5)</sup>		544,000		12/31/2008 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000

Series B. Preferred Stock	\$ 0 <sup>(4)</sup>	01/12/2006	J <sup>(5)</sup>	544,000	01/12/2009 <sup>(4)</sup>	<sup>(6)</sup>	Common Stock	544,000
---------------------------------	---------------------	------------	------------------	---------	---------------------------	----------------	-----------------	---------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SUN PHARMACEUTICAL INDUSTRIES LTD SPARC, TANDALJA VADODARA, GUJARAT, K7 309 020		X		
SUN PHARMA GLOBAL INC		X		
SHANGHVI DILIP S	X	X	Chairman of the Board	

## Signatures

/s/ Sudhir V. Valia,  
Director 01/23/2006

    Signature of Reporting  
Person Date

/s/ Sudhir V. Valia,  
Director 01/23/2006

    Signature of Reporting  
Person Date

/s/ Dilip S. Shanghi 01/23/2006

    Signature of Reporting  
Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On January 25, 2005, Sun Pharmaceutical Industries Limited ("Sun") transferred 5,131,317 shares of Common Stock to its wholly-owned subsidiary, Sun Pharma Global, Inc. ("Sun Global").
- (2) These shares are owned directly by Sun. Dilip S. Shanghi is the controlling shareholder of Sun.
- (3) These shares are owned directly by Sun Global, which is a wholly-owned subsidiary of Sun. Dilip S. Shanghi is the controlling shareholder of Sun.
- (4) The Series B preferred shares are convertible into common stock after three years (or immediately upon a change in control) on a one-to-one basis.
- (5) Sun Global earns 544,000 shares of Series B Preferred Stock for each technology transfer to Caraco of a generic drug by Sun Global when such drug passes its bioequivalency studies. In the event of the dissolution of Caraco, such shares have a preference equal to the value attributed to them on the dates on which they were earned as follows: 11-24-04 (\$5.50 per share); 12-06-04 (\$5.93 per share); 1-25-05 (\$6.65 per share); 3-05-05 (\$6.32 per share); 3-22-05 (\$5.78 per share); 5-2-05 (\$5.96 per share); 7-11-08 (\$6.37 per share); 7-14-05 (\$6.61 per share); 8-25-05 (\$6.63 per share); 10-27-05 (\$6.38 per share); 12-31-05 (\$6.74 per share); and 1-12-06 (\$7.38 per share).

Edgar Filing: SUN PHARMA GLOBAL INC - Form 4

(6) The shares of Series B Preferred Stock remain outstanding until such time as they are converted into Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.